Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Arena Pharmaceuticals stock
Own Arena Pharmaceuticals stock in just a few minutes.
Arena Pharmaceuticals, Inc is a biotechnology business based in the US. Arena Pharmaceuticals shares (ARNA) are listed on the NASDAQ and all prices are listed in US Dollars. Arena Pharmaceuticals employs 363 staff and has a trailing 12-month revenue of around USD$319,000.
How to buy shares in Arena Pharmaceuticals
- Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
- Search for Arena Pharmaceuticals. Find the stock by name or ticker symbol: ARNA. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Arena Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Arena Pharmaceuticals, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Arena Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
- ARNA shares summary
- Compare share dealing platforms
- Is ARNA stock a buy or sell?
- Stock performance over time
- Can I short ARNA shares?
- Are ARNA shares over-valued?
- Arena Pharmaceuticals's financials
- How volatile are ARNA shares?
- Does Arena Pharmaceuticals pay a dividend?
- Have ARNA shares ever split?
- Other common questions
Arena Pharmaceuticals share price
Use our graph to track the performance of ARNA stocks over time.Arena Pharmaceuticals shares at a glance
Information last updated 2021-04-08.
| 52-week range | USD$44.79 - USD$90.19 |
|---|---|
| 50-day moving average | USD$74.5547 |
| 200-day moving average | USD$75.6257 |
| Wall St. target price | USD$96.08 |
| PE ratio | 6.3979 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | USD$10.836 |
Buy Arena Pharmaceuticals shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Arena Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Is Arena Pharmaceuticals under- or over-valued?
Valuing Arena Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Arena Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Arena Pharmaceuticals's P/E ratio
Arena Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 6x. In other words, Arena Pharmaceuticals shares trade at around 6x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Arena Pharmaceuticals's PEG ratio
Arena Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.46. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Arena Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Arena Pharmaceuticals's EBITDA
Arena Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$549.8 million.
The EBITDA is a measure of a Arena Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
Arena Pharmaceuticals financials
| Revenue TTM | USD$319,000 |
|---|---|
| Gross profit TTM | USD$-323,421,000 |
| Return on assets TTM | -22.55% |
| Return on equity TTM | -37.62% |
| Profit margin | 0% |
| Book value | $18.435 |
| Market capitalisation | USD$4 billion |
TTM: trailing 12 months
Shorting Arena Pharmaceuticals shares
There are currently 4.0 million Arena Pharmaceuticals shares held short by investors – that's known as Arena Pharmaceuticals's "short interest". This figure is 15.5% up from 3.5 million last month.
There are a few different ways that this level of interest in shorting Arena Pharmaceuticals shares can be evaluated.
Arena Pharmaceuticals's "short interest ratio" (SIR)
Arena Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Arena Pharmaceuticals shares currently shorted divided by the average quantity of Arena Pharmaceuticals shares traded daily (recently around 546693.87755102). Arena Pharmaceuticals's SIR currently stands at 7.35. In other words for every 100,000 Arena Pharmaceuticals shares traded daily on the market, roughly 7350 shares are currently held short.
However Arena Pharmaceuticals's short interest can also be evaluated against the total number of Arena Pharmaceuticals shares, or, against the total number of tradable Arena Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Arena Pharmaceuticals's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Arena Pharmaceuticals shares in existence, roughly 70 shares are currently held short) or 0.0667% of the tradable shares (for every 100,000 tradable Arena Pharmaceuticals shares, roughly 67 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Arena Pharmaceuticals.
Find out more about how you can short Arena Pharmaceuticals stock.
Arena Pharmaceuticals share dividends
We're not expecting Arena Pharmaceuticals to pay a dividend over the next 12 months.
Have Arena Pharmaceuticals's shares ever split?
Arena Pharmaceuticals's shares were split on a 1:10 basis on 18 June 2017. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Arena Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Arena Pharmaceuticals shares which in turn could have impacted Arena Pharmaceuticals's share price.
Arena Pharmaceuticals share price volatility
Over the last 12 months, Arena Pharmaceuticals's shares have ranged in value from as little as $44.79 up to $90.19. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arena Pharmaceuticals's is 0.5554. This would suggest that Arena Pharmaceuticals's shares are less volatile than average (for this exchange).
Arena Pharmaceuticals overview
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase I clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Beacon Discovery; Boehringer Ingelheim International GmbH; and Eisai Co., Ltd. and Eisai Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah.
Frequently asked questions
More guides on Finder
-
How to buy Sigma Labs stock
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
-
How to buy Simpson Manufacturing CoInc stock
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
-
How to buy Sequans Communications S-A stock
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
-
How to buy SFL Corporation stock
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
-
How to buy Senmiao Technology stock
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
-
How to buy Sensata Technologies Holding stock
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
-
How to buy Select Bancorp stock
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
-
How to buy Second Sight Medical Products stock
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
-
How to buy Sibanye Stillwater stock
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
-
How to buy Shinhan Financial Group CoLtd stock
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
Ask an Expert